Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
23
ATXS Quote, Financials, Valuation and Earnings
Last price:
$9.40
Seasonality move
:
16.9%
Day range:
$9.32 - $9.63
52-week range:
$6.58 - $16.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.19x
Volume:
314.2K
Avg. volume:
363K
1-year change:
40.5%
Market cap:
$538.4M
Revenue:
--
EPS (TTM):
-$2.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATXS
Astria Therapeutics
|
-- | -- | -- | -- | -- |
|
IBIO
iBio
|
-- | -$0.46 | -100% | -89.82% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
PTN
Palatin Technologies
|
-- | -$0.51 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.25 | -- | -8.25% | $100.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATXS
Astria Therapeutics
|
$9.54 | -- | $538.4M | -- | $0.00 | 0% | -- |
|
IBIO
iBio
|
$2.42 | -- | $22.1M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.54 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
OGEN
Oragenics
|
$0.38 | -- | $4.6M | -- | $0.00 | 0% | 1.49x |
|
PTN
Palatin Technologies
|
$0.99 | -- | $19.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.76 | $100.00 | $4.9M | -- | $0.00 | 0% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATXS
Astria Therapeutics
|
-- | 3.062 | -- | -- |
|
IBIO
iBio
|
4.41% | 6.097 | 5.41% | 3.89x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 5.927 | -- | -- |
|
PTN
Palatin Technologies
|
-- | -0.872 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.027 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATXS
Astria Therapeutics
|
-- | -$29M | -- | -- | -- | -$28M |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
Astria Therapeutics vs. Competitors
-
Which has Higher Returns ATXS or IBIO?
iBio has a net margin of -- compared to Astria Therapeutics's net margin of -4444.57%. Astria Therapeutics's return on equity of -- beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics-- -$0.42 -- IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About ATXS or IBIO?
Astria Therapeutics has a consensus price target of --, signalling upside risk potential of 177.03%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 49.05%. Given that Astria Therapeutics has higher upside potential than iBio, analysts believe Astria Therapeutics is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics0 0 0 IBIOiBio0 0 0 -
Is ATXS or IBIO More Risky?
Astria Therapeutics has a beta of 0.669, which suggesting that the stock is 33.096% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.
-
Which is a Better Dividend Stock ATXS or IBIO?
Astria Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATXS or IBIO?
Astria Therapeutics quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Astria Therapeutics's net income of -$24.5M is lower than iBio's net income of -$4M. Notably, Astria Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics-- -- -- -$24.5M IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns ATXS or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Astria Therapeutics's net margin of -49.65%. Astria Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics-- -$0.42 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About ATXS or NBY?
Astria Therapeutics has a consensus price target of --, signalling upside risk potential of 177.03%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Astria Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Astria Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics0 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is ATXS or NBY More Risky?
Astria Therapeutics has a beta of 0.669, which suggesting that the stock is 33.096% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock ATXS or NBY?
Astria Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATXS or NBY?
Astria Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Astria Therapeutics's net income of -$24.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Astria Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics-- -- -- -$24.5M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns ATXS or OGEN?
Oragenics has a net margin of -- compared to Astria Therapeutics's net margin of --. Astria Therapeutics's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics-- -$0.42 -- OGENOragenics-- -$0.38 -- -
What do Analysts Say About ATXS or OGEN?
Astria Therapeutics has a consensus price target of --, signalling upside risk potential of 177.03%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 23709.52%. Given that Oragenics has higher upside potential than Astria Therapeutics, analysts believe Oragenics is more attractive than Astria Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics0 0 0 OGENOragenics0 0 0 -
Is ATXS or OGEN More Risky?
Astria Therapeutics has a beta of 0.669, which suggesting that the stock is 33.096% less volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.
-
Which is a Better Dividend Stock ATXS or OGEN?
Astria Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATXS or OGEN?
Astria Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Astria Therapeutics's net income of -$24.5M is lower than Oragenics's net income of -$2.5M. Notably, Astria Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics is -- versus 1.49x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics-- -- -- -$24.5M OGENOragenics1.49x -- -- -$2.5M
-
Which has Higher Returns ATXS or PTN?
Palatin Technologies has a net margin of -- compared to Astria Therapeutics's net margin of -2357.27%. Astria Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics-- -$0.42 -- PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About ATXS or PTN?
Astria Therapeutics has a consensus price target of --, signalling upside risk potential of 177.03%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Astria Therapeutics, analysts believe Palatin Technologies is more attractive than Astria Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics0 0 0 PTNPalatin Technologies0 0 0 -
Is ATXS or PTN More Risky?
Astria Therapeutics has a beta of 0.669, which suggesting that the stock is 33.096% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.
-
Which is a Better Dividend Stock ATXS or PTN?
Astria Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATXS or PTN?
Astria Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Astria Therapeutics's net income of -$24.5M is lower than Palatin Technologies's net income of -$7.8M. Notably, Astria Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics-- -- -- -$24.5M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns ATXS or TOVX?
Theriva Biologics has a net margin of -- compared to Astria Therapeutics's net margin of --. Astria Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics-- -$0.42 -- TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About ATXS or TOVX?
Astria Therapeutics has a consensus price target of --, signalling upside risk potential of 177.03%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 5042.05%. Given that Theriva Biologics has higher upside potential than Astria Therapeutics, analysts believe Theriva Biologics is more attractive than Astria Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics0 0 0 TOVXTheriva Biologics1 0 0 -
Is ATXS or TOVX More Risky?
Astria Therapeutics has a beta of 0.669, which suggesting that the stock is 33.096% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.
-
Which is a Better Dividend Stock ATXS or TOVX?
Astria Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATXS or TOVX?
Astria Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Astria Therapeutics's net income of -$24.5M is lower than Theriva Biologics's net income of -$7.7M. Notably, Astria Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics is -- versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics-- -- -- -$24.5M TOVXTheriva Biologics0.90x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
